- Home
- ATHA vs NRXS Comparison
ATHA vs NRXS Comparison
Compare ATHA & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- NRXS
- Stock Information
- Founded
- ATHA 2011
- NRXS 2011
- Country
- ATHA United States
- NRXS United States
- Employees
- ATHA N/A
- NRXS N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- NRXS
- Sector
- ATHA Health Care
- NRXS
- Exchange
- ATHA Nasdaq
- NRXS Nasdaq
- Market Cap
- ATHA 14.8M
- NRXS 13.0M
- IPO Year
- ATHA 2020
- NRXS 2023
- Fundamental
- Price
- ATHA $0.40
- NRXS $2.47
- Analyst Decision
- ATHA Hold
- NRXS Strong Buy
- Analyst Count
- ATHA 3
- NRXS 1
- Target Price
- ATHA $0.50
- NRXS $7.00
- AVG Volume (30 Days)
- ATHA 133.3K
- NRXS 54.4K
- Earning Date
- ATHA 08-07-2025
- NRXS 08-12-2025
- Dividend Yield
- ATHA N/A
- NRXS N/A
- EPS Growth
- ATHA N/A
- NRXS N/A
- EPS
- ATHA N/A
- NRXS N/A
- Revenue
- ATHA N/A
- NRXS $3,217,531.00
- Revenue This Year
- ATHA N/A
- NRXS $73.05
- Revenue Next Year
- ATHA N/A
- NRXS $130.42
- P/E Ratio
- ATHA N/A
- NRXS N/A
- Revenue Growth
- ATHA N/A
- NRXS 41.93
- 52 Week Low
- ATHA $0.22
- NRXS $1.33
- 52 Week High
- ATHA $3.51
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- ATHA 53.29
- NRXS 49.35
- Support Level
- ATHA $0.38
- NRXS $2.25
- Resistance Level
- ATHA $0.41
- NRXS $2.55
- Average True Range (ATR)
- ATHA 0.02
- NRXS 0.13
- MACD
- ATHA -0.00
- NRXS -0.01
- Stochastic Oscillator
- ATHA 71.70
- NRXS 64.62
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).